Lakatos Gábor, Herszényi László, Tulassay Zsolt
Semmelweis Egyetem, Altalános Orvostudományi Kar II. Belgyógyászati Klinika, Budapest.
Orv Hetil. 2008 Aug 17;149(33):1539-47. doi: 10.1556/OH.2008.28334.
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed drugs worldwide, but they can cause serious gastrointestinal (GI) side effects. NSAIDs are capable of damaging the whole gastrointestinal tract. Cyclooxygenase-2 (COX-2) inhibitors (coxibs) have been developed with the aim of maintaining the anti-inflammatory benefits but reducing gastrotoxicity. There is a good evidence that these drugs effectively prevent gastroduodenal ulcers and ulcer complications. Little is known about the side effects of these agents in the small and large intestine. There is an increasing evidence that COX-2 is constitutively expressed in the gastrointestinal tract and is important for the maintenance of bowel integrity. There have also been growing concerns about the potential for coxibs to increase the frequency of adverse cardiovascular events. The purpose of this review is to summarize recent knowledge about the safety profile of selective COX-2 inhibitors.
非甾体抗炎药(NSAIDs)是全球处方量最大的药物之一,但它们会引起严重的胃肠道(GI)副作用。NSAIDs能够损害整个胃肠道。环氧化酶-2(COX-2)抑制剂(昔布类药物)的研发目的是在保持抗炎作用的同时降低胃毒性。有充分证据表明这些药物能有效预防胃十二指肠溃疡及溃疡并发症。对于这些药物在小肠和大肠中的副作用了解甚少。越来越多的证据表明COX-2在胃肠道中持续表达,对维持肠道完整性很重要。人们也越来越担心昔布类药物会增加不良心血管事件的发生频率。本综述的目的是总结关于选择性COX-2抑制剂安全性的最新知识。